Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Optimising drug combinations for people with heart failure
+Practice
In print
PHARMACOTHERAPY
Optimising drug combinations for people with heart failure
Wednesday 12 October 2022, 12:25 AM

[Image: Ali Hajiluyi on Unsplash]
As our understanding of heart failure has increased, so too has the number of medicines used to treat it. This article summarises the optimisation and cumulative impact of heart failure treatments
Key points, Optimisation of therapy extends life expectancy for those with heart failure.
For heart failure with reduced ejection fraction (≤35 per cent), those, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Troughton R. Heart failure: what a GP needs to know in 2020. Research Review Speaker Series 2020.
- Ministry of Health. Cardiovascular disease. August 2018.
- McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993–1004.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383(15):1413–24.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451–61.
- Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020;396(10244):121–28.